369 related articles for article (PubMed ID: 33048619)
1. Molecular Landscape and Actionable Alterations in a Genomically Guided Cancer Clinical Trial: National Cancer Institute Molecular Analysis for Therapy Choice (NCI-MATCH).
Flaherty KT; Gray RJ; Chen AP; Li S; McShane LM; Patton D; Hamilton SR; Williams PM; Iafrate AJ; Sklar J; Mitchell EP; Harris LN; Takebe N; Sims DJ; Coffey B; Fu T; Routbort M; Zwiebel JA; Rubinstein LV; Little RF; Arteaga CL; Comis R; Abrams JS; O'Dwyer PJ; Conley BA;
J Clin Oncol; 2020 Nov; 38(33):3883-3894. PubMed ID: 33048619
[TBL] [Abstract][Full Text] [Related]
2. The Molecular Analysis for Therapy Choice (NCI-MATCH) Trial: Lessons for Genomic Trial Design.
Flaherty KT; Gray R; Chen A; Li S; Patton D; Hamilton SR; Williams PM; Mitchell EP; Iafrate AJ; Sklar J; Harris LN; McShane LM; Rubinstein LV; Sims DJ; Routbort M; Coffey B; Fu T; Zwiebel JA; Little RF; Marinucci D; Catalano R; Magnan R; Kibbe W; Weil C; Tricoli JV; Alexander B; Kumar S; Schwartz GK; Meric-Bernstam F; Lih CJ; McCaskill-Stevens W; Caimi P; Takebe N; Datta V; Arteaga CL; Abrams JS; Comis R; O'Dwyer PJ; Conley BA;
J Natl Cancer Inst; 2020 Oct; 112(10):1021-1029. PubMed ID: 31922567
[TBL] [Abstract][Full Text] [Related]
3. Actionable Tumor Alterations and Treatment Protocol Enrollment of Pediatric and Young Adult Patients With Refractory Cancers in the National Cancer Institute-Children's Oncology Group Pediatric MATCH Trial.
Parsons DW; Janeway KA; Patton DR; Winter CL; Coffey B; Williams PM; Roy-Chowdhuri S; Tsongalis GJ; Routbort M; Ramirez NC; Saguilig L; Piao J; Alonzo TA; Berg SL; Fox E; Hawkins DS; Abrams JS; Mooney M; Takebe N; Tricoli JV; Seibel NL;
J Clin Oncol; 2022 Jul; 40(20):2224-2234. PubMed ID: 35353553
[TBL] [Abstract][Full Text] [Related]
4. National Cancer Institute Combination Therapy Platform Trial with Molecular Analysis for Therapy Choice (ComboMATCH).
Meric-Bernstam F; Ford JM; O'Dwyer PJ; Shapiro GI; McShane LM; Freidlin B; O'Cearbhaill RE; George S; Glade-Bender J; Lyman GH; Tricoli JV; Patton D; Hamilton SR; Gray RJ; Hawkins DS; Ramineni B; Flaherty KT; Grivas P; Yap TA; Berlin J; Doroshow JH; Harris LN; Moscow JA
Clin Cancer Res; 2023 Apr; 29(8):1412-1422. PubMed ID: 36662819
[TBL] [Abstract][Full Text] [Related]
5. Next generation sequencing of vitreoretinal lymphomas from small-volume intraocular liquid biopsies: new routes to targeted therapies.
Cani AK; Hovelson DH; Demirci H; Johnson MW; Tomlins SA; Rao RC
Oncotarget; 2017 Jan; 8(5):7989-7998. PubMed ID: 28002793
[TBL] [Abstract][Full Text] [Related]
6. Defining precision: The precision medicine initiative trials NCI-MPACT and NCI-MATCH.
Coyne GO; Takebe N; Chen AP
Curr Probl Cancer; 2017; 41(3):182-193. PubMed ID: 28372823
[TBL] [Abstract][Full Text] [Related]
7. Perspectives on research activity in the USA on Cancer Precision Medicine.
Bando H; Takebe N
Jpn J Clin Oncol; 2016 Feb; 46(2):106-10. PubMed ID: 26531706
[TBL] [Abstract][Full Text] [Related]
8. Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial.
Le Tourneau C; Delord JP; Gonçalves A; Gavoille C; Dubot C; Isambert N; Campone M; Trédan O; Massiani MA; Mauborgne C; Armanet S; Servant N; Bièche I; Bernard V; Gentien D; Jezequel P; Attignon V; Boyault S; Vincent-Salomon A; Servois V; Sablin MP; Kamal M; Paoletti X;
Lancet Oncol; 2015 Oct; 16(13):1324-34. PubMed ID: 26342236
[TBL] [Abstract][Full Text] [Related]
9. Clinical Trial Accrual Targeting Genomic Alterations After Next-Generation Sequencing at a Non-National Cancer Institute-Designated Cancer Program.
Mantripragada KC; Olszewski AJ; Schumacher A; Perez K; Birnbaum A; Reagan JL; Mega A; Khurshid H; Bartley C; Lombardo A; Rossiter R; Papa A; Bakalarski P; Safran H
J Oncol Pract; 2016 Apr; 12(4):e396-404. PubMed ID: 26907448
[TBL] [Abstract][Full Text] [Related]
10. The Molecular Tumor Board of the Regina Elena National Cancer Institute: from accrual to treatment in real-world.
Giacomini P; Valenti F; Allegretti M; Pallocca M; De Nicola F; Ciuffreda L; Fanciulli M; Scalera S; Buglioni S; Melucci E; Casini B; Carosi M; Pescarmona E; Giordani E; Sperati F; Jannitti N; Betti M; Maugeri-Saccà M; Cecere FL; Villani V; Pace A; Appetecchia M; Vici P; Savarese A; Krasniqi E; Ferraresi V; Russillo M; Fabi A; Landi L; Minuti G; Cappuzzo F; Zeuli M; Ciliberto G
J Transl Med; 2023 Oct; 21(1):725. PubMed ID: 37845764
[TBL] [Abstract][Full Text] [Related]
11. Utility of incorporating next-generation sequencing (NGS) in an Asian non-small cell lung cancer (NSCLC) population: Incremental yield of actionable alterations and cost-effectiveness analysis.
Tan AC; Lai GGY; Tan GS; Poon SY; Doble B; Lim TH; Aung ZW; Takano A; Tan WL; Ang MK; Tan BS; Devanand A; Too CW; Gogna A; Ong BH; Koh TPT; Kanesvaran R; Ng QS; Jain A; Rajasekaran T; Lim AST; Lim WT; Toh CK; Tan EH; Lim TKH; Tan DSW
Lung Cancer; 2020 Jan; 139():207-215. PubMed ID: 31835042
[TBL] [Abstract][Full Text] [Related]
12. Considerations of developing an NGS assay for clinical applications in precision oncology: The NCI-MATCH NGS assay experience.
Lih CJ; Takebe N
Curr Probl Cancer; 2017; 41(3):201-211. PubMed ID: 28625332
[TBL] [Abstract][Full Text] [Related]
13. Tumor-Specific Activity of Precision Medicines in the NCI-MATCH Trial.
Zhou I; Plana D; Palmer AC
Clin Cancer Res; 2024 Feb; 30(4):786-792. PubMed ID: 38109210
[TBL] [Abstract][Full Text] [Related]
14. Discovery of actionable genetic alterations with targeted panel sequencing in children with relapsed or refractory solid tumors.
Lee JW; Kim NKD; Lee SH; Cho HW; Ma Y; Ju HY; Yoo KH; Sung KW; Koo HH; Park WY
PLoS One; 2019; 14(11):e0224227. PubMed ID: 31747416
[TBL] [Abstract][Full Text] [Related]
15. Clinical Actionability of Comprehensive Genomic Profiling for Management of Rare or Refractory Cancers.
Hirshfield KM; Tolkunov D; Zhong H; Ali SM; Stein MN; Murphy S; Vig H; Vazquez A; Glod J; Moss RA; Belyi V; Chan CS; Chen S; Goodell L; Foran D; Yelensky R; Palma NA; Sun JX; Miller VA; Stephens PJ; Ross JS; Kaufman H; Poplin E; Mehnert J; Tan AR; Bertino JR; Aisner J; DiPaola RS; Rodriguez-Rodriguez L; Ganesan S
Oncologist; 2016 Nov; 21(11):1315-1325. PubMed ID: 27566247
[TBL] [Abstract][Full Text] [Related]
16. Multicenter experience with large panel next-generation sequencing in patients with advanced solid cancers in Japan.
Kato S; Hayashi T; Suehara Y; Hamanoue H; Yamanaka S; Ichikawa Y; Higurashi T; Ohashi K; Yamaguchi S; Nozaki Y; Terao Y; Saito T
Jpn J Clin Oncol; 2019 Feb; 49(2):174-182. PubMed ID: 30541038
[TBL] [Abstract][Full Text] [Related]
17. Molecular Profiling-Based Assignment of Cancer Therapy (NCI-MPACT): A Randomized Multicenter Phase II Trial.
Chen AP; Kummar S; Moore N; Rubinstein LV; Zhao Y; Williams PM; Palmisano A; Sims D; O'Sullivan Coyne G; Rosenberger CL; Simpson M; Raghav KPS; Meric-Bernstam F; Leong S; Waqar S; Foster JC; Konaté MM; Das B; Karlovich C; Lih CJ; Polley E; Simon R; Li MC; Piekarz R; Doroshow JH
JCO Precis Oncol; 2021; 5():. PubMed ID: 33928209
[TBL] [Abstract][Full Text] [Related]
18. Cancer Therapy Directed by Comprehensive Genomic Profiling: A Single Center Study.
Wheler JJ; Janku F; Naing A; Li Y; Stephen B; Zinner R; Subbiah V; Fu S; Karp D; Falchook GS; Tsimberidou AM; Piha-Paul S; Anderson R; Ke D; Miller V; Yelensky R; Lee JJ; Hong DS; Kurzrock R
Cancer Res; 2016 Jul; 76(13):3690-701. PubMed ID: 27197177
[TBL] [Abstract][Full Text] [Related]
19. Comprehensive tumor profiling-guided therapy in rare or refractory solid cancer: A feasibility study in daily clinical practice.
Ibrahim T; Ahmadie A; Rassy E; Karak FE; Hanna C; Farhat F; Kattan J; Ghosn M
Bull Cancer; 2020 Apr; 107(4):410-416. PubMed ID: 32145962
[TBL] [Abstract][Full Text] [Related]
20. Molecular Screening for Cancer Treatment Optimization (MOSCATO-01) in Pediatric Patients: A Single-Institutional Prospective Molecular Stratification Trial.
Harttrampf AC; Lacroix L; Deloger M; Deschamps F; Puget S; Auger N; Vielh P; Varlet P; Balogh Z; Abbou S; Allorant A; Valteau-Couanet D; Sarnacki S; Gamiche-Rolland L; Meurice G; Minard-Colin V; Grill J; Brugieres L; Dufour C; Gaspar N; Michiels S; Vassal G; Soria JC; Geoerger B
Clin Cancer Res; 2017 Oct; 23(20):6101-6112. PubMed ID: 28733441
[No Abstract] [Full Text] [Related]
[Next] [New Search]